Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
|ClinicalTrials.gov Identifier: NCT00889525|
Recruitment Status : Completed
First Posted : April 29, 2009
Last Update Posted : April 29, 2009
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.
Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.
|Condition or disease||Intervention/treatment||Phase|
|Cushing's Disease Corticotroph Adenoma||Drug: Cabergoline||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor|
|Study Start Date :||November 2007|
U.S. FDA Resources
Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
- Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00889525
|Seth GSMC & KEM hospital|
|Mumbai, Maharashtra, India, 4000012|
|Principal Investigator:||Nalini S Shah, DM||Seth GSMC and KEM hospital, Mumbai|